We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-21.9%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.8B
AUM Growth
-$63.5M
Cap. Flow
+$448M
Cap. Flow %
24.92%
Top 10 Hldgs %
55.9%
Holding
105
New
11
Increased
30
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$58.4M
2
NVRO
NEVRO CORP.
NVRO
+$57.5M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$30.2M
4
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18.2M
5
MASI
Masimo
MASI
+$17.2M

Top Sells

Rank Stock Value
1
ASRT
Assertio
ASRT
+$25.1M
2
ALR
Alere Inc
ALR
+$23.9M
3
HRTX icon
Heron Therapeutics
HRTX
+$17.8M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$12.8M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 63.28%
2 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPPI
26
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$15.1M 0.84%
2,516,748
-133,252
-5% -$925K
TLGT
27
DELISTED
Teligent, Inc
TLGT
$15M 0.83%
228,773
– –
EGLT
28
DELISTED
Egalet Corporation
EGLT
$15M 0.83%
1,134,750
+700,000
+161% +$8.89M
ZGNX
29
DELISTED
Zogenix, Inc.
ZGNX
$14.9M 0.83%
1,107,205
-235,001
-18% -$4.24M
AMPH icon
30
Amphastar Pharmaceuticals
AMPH
$825M
$14.9M 0.83%
1,276,979
-140,977
-10% -$2.11M
ATRS
31
DELISTED
Antares Pharma, Inc.
ATRS
$14.4M 0.8%
8,475,000
+900,000
+12% +$1.76M
RIGL icon
32
Rigel Pharmaceuticals
RIGL
$680M
$12.7M 0.7%
512,528
-75,147
-13% -$2.24M
CPRX
33
DELISTED
Catalyst Pharmaceutical
CPRX
$12.6M 0.7%
4,183,177
– –
HTWR
34
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$12.5M 0.7%
+239,675
New +$18.2M
HRTX icon
35
CALL
Heron Therapeutics
HRTX
$86.3M
$12.2M 0.68%
+500,000
New +$16.7M
IOVA icon
36
Iovance Biotherapeutics
IOVA
$2.23B
$12.1M 0.67%
2,105,519
+293,100
+16% +$2.28M
GNMX
37
DELISTED
Aevi Genomic Medicine Inc
GNMX
$12.1M 0.67%
1,545,306
+431,406
+39% +$3.34M
QLTI
38
DELISTED
QLT Inc
QLTI
$11.8M 0.66%
4,445,527
– –
TRVN
39
DELISTED
Trevena, Inc.
TRVN
$11.2M 0.62%
1,725
-530
-24% -$2.62M
DSCI
40
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$11.1M 0.62%
2,362,104
+44,615
+2% +$288K
PETX
41
DELISTED
Aratana Therapeutics, Inc.
PETX
$11.1M 0.62%
1,309,865
+178,000
+16% +$3.01M
RDHL
42
Redhill Biopharma
RDHL
$3.85M
$10.7M 0.6%
830
+446
+116% +$6.6M
SPNC
43
DELISTED
Spectranetics Corp
SPNC
$10.6M 0.59%
+900,249
New +$16.1M
MRTX
44
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.2M 0.57%
295,700
-63,961
-18% -$1.93M
TVTX icon
45
CALL
Travere Therapeutics
TVTX
$5.33B
$10.1M 0.56%
+500,000
New +$14.8M
PRTK
46
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.1M 0.56%
530,283
– –
HZNP
47
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.91M 0.55%
500,000
-600,000
-55% -$19M
ARDX icon
48
Ardelyx
ARDX
$1.24B
$9.49M 0.53%
549,290
-100,000
-15% -$1.87M
ARCT icon
49
Arcturus Therapeutics
ARCT
$157M
$9.4M 0.52%
222,444
-3,243
-1% -$171K
NVRO
50
CALL
DELISTED
NEVRO CORP.
NVRO
$9.28M 0.52%
+200,000
New +$9.69M
1
2
3 4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Broadfin Capital held 105 positions worth $1.8B, down 3.4% from $1.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Broadfin Capital deployed $448M of net new capital in Q3 2015, opening 11 new positions and adding to 30 existing holdings. Its largest new stake was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Heron Therapeutics, an estimated $17.8M trimmed.

  • Broadfin Capital's largest Q3 2015 buy was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015, an estimated $58.4M increase.
  • Broadfin Capital's biggest Q3 2015 reduction was Heron Therapeutics, cutting an estimated $17.8M.
  • Broadfin Capital fully exited Assertio in Q3 2015, selling an estimated $25.1M.
  • Broadfin Capital's ten largest holdings make up 56% of its $1.8B portfolio in Q3 2015.
  • Broadfin Capital opened 11 new positions and closed 15 in Q3 2015.
  • Broadfin Capital's portfolio value fell 3.4% quarter-over-quarter to $1.8B.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.